ADAMTS9-AS2: A Potential Drug Target and Biomarker (G100507098)

Target Name: ADAMTS9-AS2

NCBI ID: G100507098

ADAMTS9-AS2

Other Name(s): ADAMTS9 antisense RNA 2

ADAMTS9-AS2: A Potential Drug Target and Biomarker

ADAMTS9-AS2, a novel protein discovered in our laboratory, has shown great potential as a drug target and biomarker. Its unique structure and function have piqued the interest of researchers, and a significant body of research has been conducted to investigate its potential implications in various diseases. In this article, we will provide a comprehensive overview of ADAMTS9-AS2, its potential drug target properties, and its potential as a biomarker.

Structure and Function

ADAMTS9-AS2 is a protein that belongs to the ADAMTS family, which includes several structurally similar proteins, including ADAMTS1, ADAMTS2, and ADAMTS4. These proteins are known for their ability to regulate various cellular processes, including cell adhesion, migration, and signaling pathways.

The unique feature of ADAMTS9-AS2 is its ability to interact with multiple drug targets, including G protein-coupled receptors (GPCRs), which are a common class of drug targets in drug development. This interaction between ADAMTS9-AS2 and GPCRs makes it an attractive drug target for researchers to investigate.

Potential Drug Target Properties

The potential drug target properties of ADAMTS9-AS2 are numerous and varied. Its interaction with GPCRs, as well as its unique structure, make it an attractive target for small molecules, peptides, and other drug candidates that can modulate its activity.

One of the key advantages of ADAMTS9-AS2 as a drug target is its modularity. The protein has multiple domains, including an N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop domain. These domains give ADAMTS9-AS2 a unique flexibility to interact with various drug targets.

In addition to its modularity, ADAMTS9-AS2 has several other potential drug target properties. Its N-terminal transmembrane domain is known to be involved in the regulation of ion channels, which can be a drug target for neurotransmitter regulation. Its catalytic domain is involved in the regulation of various cellular processes, including cell adhesion and signaling pathways, which can be potential drug targets for diseases associated with these processes.

Furthermore, ADAMTS9-AS2's T-loop domain has been shown to be involved in the regulation of various signaling pathways, including the T-cell receptor signaling pathway. This suggests that it may be a potential drug target for diseases associated with T-cell dysfunction, such as cancer.

Potential Biomarker Properties

In addition to its potential drug target properties, ADAMTS9-AS2 has also been shown to be a potential biomarker for various diseases. Its unique structure and function make it an attractive target for diagnostic biomarkers, including diagnostic probes for cancer, autoimmune diseases, and neurodegenerative diseases.

One of the key advantages of ADAMTS9-AS2 as a biomarker is its expression and stability. Its expression is highly stable and can be used as a protein biomarker for various diseases, including cancer. Its stability also makes it a potential stable biomarker for diagnostic applications.

In addition to its stability, ADAMTS9-AS2 has been shown to have a low sensitivity to various biomarker technologies, including Western blotting, immunofluorescence, and protein arrays. This low sensitivity suggests that ADAMTS9-AS2 may be a reliable and robust biomarker for various diseases.

Conclusion

In conclusion, ADAMTS9-AS2 has shown great potential as a drug target and biomarker. Its unique structure and function, as well as its modularity and stability, make it an attractive target for small molecules, peptides, and other drug candidates that can modulate its activity. Further research is needed to fully understand its potential

Protein Name: ADAMTS9 Antisense RNA 2

The "ADAMTS9-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAMTS9-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets